The American Psychiatric Association recently outlined ways that biomarkers—biological indicators of mental illness detectable through diagnostic tests—could be incorporated into future versions of the Diagnostic and Statistical Manual of Mental Disorders (DSM). Historically, mental illnesses have been diagnosed and treated based primarily on outward symptoms, but biomarkers could fundamentally change psychiatric practice by enabling more objective diagnoses and targeted treatment selection.
Current Research and Promising Biomarkers
Psychiatric biomarkers are not yet ready for widespread clinical use, but several show promise. In depression, for example, about a quarter of patients have elevated levels of an inflammatory protein called C-reactive protein, detectable through a blood test. Research has shown that people with high levels of this protein seem to respond better to drugs that alter dopamine levels in the brain, rather than selective serotonin reuptake inhibitors (SSRIs), a common type of antidepressant. The APA’s paper indicates that proposed biomarkers could include tests for brain activity, genetic profiles, or immune markers associated with certain psychiatric conditions, including schizophrenia and substance use disorders.
Clinical Impact and Treatment Efficiency
Currently, prescribing psychiatric medications can be “a bit of a crapshoot,” according to Matthew Eisenberg, director of the Center for Mental Health and Addiction Policy at Johns Hopkins University Bloomberg School of Public Health. In a seminal early 2000s trial funded by the National Institute of Mental Health, about 30% of participants with depression saw symptoms disappear with their first antidepressant treatment. If patients’ biology suggested they’d respond better to one treatment than another, doctors could avoid wasting time on ineffective medications. Jonathan Alpert, an author of the APA’s January paper and vice chair of its Future DSM Strategic Committee, stated that access to test results could “streamline insurance coverage decisions and help clinicians make faster and more accurate diagnoses and treatment recommendations.”
Challenges and Concerns
Researchers emphasize that psychiatric biomarkers still need to be “robustly validated” and require “a coordinated, well-funded research effort.” Additionally, experts have raised concerns about implementation challenges, including costs, insurance coverage, and patient privacy. Some researchers worry insurers or employers could discriminate against people whose biological profiles suggest risk for serious neuropsychiatric conditions. Gabriel Lázaro-Muñoz from Harvard Medical School’s Center for Bioethics called it a “critical moment” to consider legislative protections. Andrew Miller, a professor of psychiatry at Emory University School of Medicine, characterizes the APA’s embrace of biomarkers as signaling “the beginning of a revolution,” recognizing that “what we’ve done up to this point has not been good enough, and we can do better.”
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.arcamax.com/healthtips/s-4050553